Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P200 | ISIN: KYG0146B1032 | Ticker-Symbol: 4RY
Tradegate
27.06.25 | 12:05
9,850 Euro
-2,48 % -0,250
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
AKESO INC Chart 1 Jahr
5-Tage-Chart
AKESO INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,90010,20013:03
9,90010,30027.06.

Aktuelle News zur AKESO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.06.Akeso, Inc.: Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025384HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16...
► Artikel lesen
11.06.AKESO (09926): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, JUNE 30, 20252
AKESO Aktie jetzt für 0€ handeln
11.06.AKESO (09926): NOTICE OF EXTRAORDINARY GENERAL MEETING2
11.06.AKESO (09926): PROPOSED GRANT OF SHARE OPTIONS AND RSUS TO DR. XIA AND NOTICE OF EXTRAORDINARY GENERAL MEETING1
05.06.Akeso gains NMPA approval for cadonilimab to treat cervical cancer14
05.06.Akeso's Cadonilimab Gets NMPA Approval For First-line Cervical Cancer Treatment1
05.06.AKESO (09926): VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE SNDA FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER2
04.06.JPMorgan senkt Kursziel für Akeso wegen US-Regulierungsbedenken6
04.06.JPMorgan lowers Akeso stock price target due to US regulatory concerns2
02.06.Jefferies: HARMONi Trial Confirms CN Data Credibility; AKESO (09926.HK) TP $1504
30.05.Akeso, Summit's ivonescimab delayed progression by 48% in certain lung cancers in first global phase 3 readout9
26.05.AKESO (09926): GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS1
14.05.DelveInsight Business Research, LLP: Akeso's Penpulimab Approval Intensifies the Competition Among the Other Pharmaceutical Companies Active in the Nasopharyngeal Carcinoma Market | DelveInsight640The FDA has approved Akeso's PD-1 monoclonal antibody, penpulimab-kcqx, for the treatment of recurrent or metastatic non-keratinising nasopharyngeal carcinoma in adults. The approval includes...
► Artikel lesen
29.04.AKESO (09926): NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF ...-
29.04.AKESO (09926): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF ...-
29.04.AKESO (09926): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT-
29.04.AKESO (09926): 2024 ANNUAL REPORT3
28.04.New Akeso, Summit data stir debate on PD-1/VEGF drugs4
28.04.'Deviated from core': Akeso CEO tries to reset expectations of bispecific's survival readout amid market tumult4
25.04.Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trial3
Weiter >>
56 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3